Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 17/20 | 0.53 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749012 | 0.83 | ICAM1 (0.60) | ICAM1VCAM1 | |
| SCHEMBL6752111 | 0.81 | ICAM1 (0.54) | ICAM1VCAM1 | |
| SCHEMBL6747281 | 0.81 | KDM4E (0.51) | ICAM1VCAM1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6747170 | 0.81 | ICAM1 (0.51) | ICAM1VCAM1GAAMAPTSMN1; SMN2 | |
| SCHEMBL6749364 | 0.79 | ICAM1 (0.56) | ICAM1 | |
| SCHEMBL6751955 | 0.78 | ICAM1 (0.52) | ICAM1VCAM1GAAMAPTSMN1; SMN2 | |
| SCHEMBL6749338 | 0.77 | ICAM1 (0.55) | ICAM1 | |
| SCHEMBL6749380 | 0.76 | ICAM1 (0.58) | ICAM1VCAM1GAAMAPTSMN1; SMN2 | |
| SCHEMBL6747641 | 0.76 | ICAM1 (0.53) | ICAM1GAAMAPTSMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL6749421 | 0.76 | ICAM1 (0.60) | ICAM1VCAM1GAAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | ICAM1 412/4885VCAM1 195/4885HTT 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.